Trial Profile
PHASE 1, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF DS-8273A IN SUBJECTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 8273 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Daiichi Sankyo Inc
- 05 Apr 2017 Results (n=16) presented at the 108th Annual Meeting of the American Association for Cancer Research
- 03 Jan 2017 Results published in the Investigational New Drugs
- 13 Dec 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research